More importantly, the relationship between NRAS and MAPK signaling in tumors has been also reported before, such as Christian Adam et al found that the co-inhibition of ERK1/2 and ERK5 MAPK pathways can effectively suppress NRAS-driven melanoma [55], and in addition, Wei Song et al verified that HBx mediated TRERNA1 elevation leads to resistance of sorafenib and HCC cell proliferation through miR-22-3p/NRAS axis [56]. Here, MAPK3 is linked to melanoma.